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 ABSTRACT 
While there is an extensive literature on the use of psychotropic medications among 
individuals with mental retardation, little of it has focused on the reasons for these prescriptions. 
Researchers have shown that the prevalence of psychotropic medication use among individuals with 
mental retardation is relatively high when compared to people with other disabilities and that the 
reasons for these drug prescriptions may not be based on rational pharmacotherapy.  Data is needed 
on the prescribing physician’s adherence to consensus guidelines or algorithms developed to 
enhance rational psychopharmacotherapy.  In order to do this, the rationales being used by 
physicians when they decide to prescribe a medication must first be examined.  The current study 
examines the approaches to medication prescription taken by physicians at one state facility.  The 
results of this study showed that physicians at this particular facility for individuals with 
developmental disabilities typically used a primary illness approach in prescribing psychotropic 
medication.  The results also showed that, in general, the documentation in the charts regarding 
assessments, diagnostic formulation, differential diagnosis, and rationale of pharmacotherapy was 




 Psychotropic medications are prescribed to treat a myriad of behavioral and psychiatric 
symptoms in both the general population and in individuals with mental retardation (Advocat, 
Mayville, & Matson, 2000; Singh & Winton, 1989; Young & Hawkins, 2002).  In the field of mental 
retardation, psychotropic medications are typically used to reduce maladaptive behavior such as 
aggression, pica, property destruction, and self-injury (Aman, Singh, & Fitzpatrick, 1987; Aman, 
Singh, & White, 1987; Intagliata & Rinck, 1985).  As such, individuals with mental retardation may 
be prescribed psychotropic medication for suppressing behavior rather than treating a psychiatric 
disorder (Aman & Singh, 1991). 
As many individuals with mental retardation are non-verbal, they must find other means to 
communicate or control their environment.  Researchers suggest that individuals with mental 
retardation who have limited communication skills use expressive behavior to communicate their 
wants and needs (Dura, 1997; Durand & Carr, 1991).  In fact, limited communication skills can lead 
to communication in the form of aggression, self-injury, or self-stimulatory behavior (Menolascino, 
Levitas, & Greiner, 1986).  Therefore, aggression, property destruction, self-injury and other socially 
inappropriate behaviors may serve a functional purpose for an individual (Carr & Durand, 1985).  
As psychotropic medications may cause side effects that cause some degree of behavioral or 
cognitive impairment, these drugs may be suppressing the individuals’ ability to functionally 
communicate (Lowry & Sovner, 1991). 
Research on the functional aspects of an individuals’ behavior, determining what motivates 
an individual to engage in a particular behavior, has yielded several technologies designed for 
assessing an individual’s behavior.  Assessment techniques based on various operant procedures 
include functional analysis (Iwata, Dorsey, Slifer, Bauman, & Richman, 1982), functional assessment 
(Hile & Desrochers, 1993), functional communication training (Carr & Durand, 1985), and positive 
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 behavior supports (Carr et al., 2002).  The aim of these assessments is to determine the function of 
an individual’s behavior and use this information to design interventions that teach the individual 
socially appropriate, functionally alternative replacement behaviors.  The efficacy of these behavioral 
assessment methods has been documented in the literature.  However, teaching an individual the 
new skills they need relies on the individual being able to learn.  As mental retardation is primarily a 
learning disorder and psychotropic medications may impair learning, these medications may reduce 
an individual’s chances for success and negatively impact on their quality of life (Lowry & Sovner, 
1991).  Given the existence of procedures that teach individuals skills that enable them to 
communicate appropriately and effectively, it may not be appropriate to treat problems that are 
behavioral and functional in nature with psychotropic medication. 
Literature on psychotropic medication has strongly indicated a link to an increased risk of 
serious side effects; of particular concern to individuals with mental retardation are side effects that 
may interfere with learning (Advocat, Mayville, & Matson, 2000; Maxmen & Ward, 2002; 
Schatzberg, Cole & DeBattista, 2003).  Some of these side effects include cognitive slowing, loss of 
creativity, memory problems, confusion, sedation, akathisia, akinesia, noncompliance and blurred 
vision (Baumeister, Sevin, King, 1998; Janicak, Davis, Preskorn, & Ayd, 2001; Schatzberg, Cole & 
DeBattista, 2003).  Further, as individuals with mental retardation generally have more health 
problems than individuals without, the risk of side effects among individuals with mental retardation 
is greater and further reaching and the use of psychotropic medication needs to be approached more 
carefully (Janicki et al., 2002; Mulligan Ault, Guy, Rues, Noto, & Guess, 1994; Springer, 1987).  
However, this does not seem to be the case.  For example, one study found that 62% of individuals 
in their sample were prescribed psychotropic medications without a valid documented psychiatric 
diagnosis (Bisconer, Sine, & Zhang, 1996).  This case may not be an isolated one. 
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  While a body of literature on the use of psychotropic medications among individuals with 
mental retardation exists, it is limited in that it has been focused primarily on prevalence rates and 
patterns of prescription rather than on the primary reasons for drug prescription (Young & 
Hawkins, 2002).  Few studies have examined why individuals with mental retardation are prescribed 
psychotropic medications, and fewer have examined the legitimacy of these prescriptions.  Unless a 
careful and thorough assessment indicates that an individual with mental retardation engages in 
behavior problems that are a feature of an underlying mental illness that may be responsive to 
psychotropic drug therapy, the use of these drugs should be considered inappropriate treatment to 
control an individual’s behavior (Sovner, 1989).  In fact, it may be considered a form of chemical 
restraint if the medication is prescribed solely for behavioral control and to such a point they cannot 
learn or function.  For psychotropic medication prescription to be considered legitimate, it should 
target the behavioral end-point(s) of a specific psychiatric disorder as defined in the DSM-IV-TR 
(APA, 2000), or have a specific behavioral-psychopharmacologic hypothesis. 
The practice of prescribing medication for behavioral control tends to ignore the bi-
directionality of drug and psychosocial interventions.  For example, self-injury has been shown to 
respond to both pharmacological and behavioral treatments (Mace, Blum, Sierp, Delaney, & Mauk, 
2001).  Behavioral treatments operate on the premise that the behavior is controlled and maintained 
by the environment.  Pharmacological treatments are based on the hypothesis that the behavior may 
be caused by an underlying chemical imbalance.  Thus, a bio-behavioral assessment and diagnostic 
system could be used to differentiate between conditions most likely to respond to behavioral 
treatments and those most likely to respond to pharmacological treatments.  If the assessment 
reveals that an individual’s self-injury is a mixed type, that is part behavioral and part biological, then 
treatment would consist of both behavioral and pharmacological components.  Both behavioral and 
drug treatments produce changes in the individual.  As these changes are reinforced in the 
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 individual’s environment, the need for medication can decrease and the need for skills training to 
maintain and continue the reduction of the behavioral aspect of self-injury could increase, or vice 
versa.  This bi-directionality of the effects of interventions is rarely appreciated when 
psychopharmacological and non-psychopharmacological interventions are developed for people in 
general, let alone individuals with developmental disabilities (Napolitano et al., 1999).  The lesson 
here is that the impact of all interventions must be constantly evaluated to account for and respond 
to changes in the individual and their environment. 
The literature on current drug prescribing practices indicates that comprehensive process 
and outcome evaluations are rarely performed and the needs of individuals with mental retardation 
are not being fully met (Hellings, 1999; Sevin et al., 2001).  It is evident that a closer look at the 
prescription patterns of psychotropic medications is warranted.  Individuals with mental retardation 
depend on professionals to teach them the skills they need in order to have the highest quality of life 
possible (Matson, Bamburg, Smalls, & Smiroldo, 1997; Menolascino et al., 1986).  Simply prescribing 
medication to treat behavioral symptomology ignores the fact that drugs do not target the cause of 
the behavior problem or the individual’s vulnerability to it.  That is, while medications may 
physiologically reduce behavioral symptoms, the individual has not learned anything and is still 
vulnerable to the internal and external environmental triggers of the particular problem behavior 
(Zuckerman, 1999).  Using psychotropic medications among individuals with mental retardation 
needs to be carefully considered and, if their use is deemed appropriate, they should be monitored 
closely to ensure that the individuals are receiving the best possible treatment according to current 
best practice. 
Ideally, the use of psychotropic medication involves matching specific label and clinically 
validated off-label uses of the medication to the specific signs and symptoms of a psychiatric 
disorder or a well-defined behavioral target (Reiss & Aman, 1998).  Psychotropic medication 
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 prescriptions should be specific as to what particular signs and symptoms of a disorder are being 
targeted.  For example, for an individual with depression it is important to know if the medication is 
targeting weight loss, insomnia, lethargy, or mood; for ADHD, is the medication targeting 
symptoms such as difficulty sustaining attention, being easily distracted, or fidgeting.  As 
psychotropic medications do not treat entire symptom profiles, it is important to know which 
symptoms are being targeted so that supplemental therapies may be introduced to treat other 
symptoms that may have a behavioral, or learned, component.  In this manner, a clinician can 
properly monitor the individual’s progress objectively and ensure that the prescribed treatments are 
appropriate.  In order to examine how well a particular psychotropic medication fits the individual’s 
diagnosis and target symptoms, we must first examine what approaches physicians are taking to 
prescribing medications to individuals with mental retardation. 
There are three ways of conceptualizing psychopharmacotherapy in people with mental 
retardation, including (a) a target symptom approach, (b) a primary illness approach, and (c) a 
behavioral-pharmacologic hypothesis approach.  The target symptom approach is based on the 
notion that if a clinician does not know or cannot unravel the biomedical or behavioral basis of a 
target behavior, the behavior can still be treated directly without knowing the underlying cause 
(Conner, 2002; Rush & Francis, 2000).  For example, aggression that has an explosive and rageful 
quality to it and is often seen as a behavioral expression of several psychiatric disorders (e.g., 
conduct disorder in children, antisocial personality disorder in adults) is medication responsive.  
Regardless of the actual psychiatric diagnosis, the overt aggression can be treated with psychotropic 
medications.  For example, overt aggression associated with explosive rage can be treated with 
atypical antipsychotic medications and lithium, aggression associated with affective lability can be 
treated with mood stabilizers, and those associated with autonomic nervous system (ANS) 
overarousal can be treated with adrenergics, Clonidine, Guanfacine and β - blockers.  This approach 
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 is analogous to palliative medical treatment when the underlying medical illness is not known or not 
treatable. 
 The primary illness approach assumes that we can treat the underlying condition, thereby 
taking care of the associated symptoms without directly treating them (Conner, 2002; Rush & 
Francis, 2000).  That is, we can identify the psychiatric disorder that underlies the target behavior 
and the psychiatric illness itself is amenable to psychopharmacological treatment.  For example, if 
the aggression is a behavioral manifestation of the underlying psychosis or mood disorder, then it 
will decrease when the underlying psychosis or mood is treated with medication.  This treatment is 
not palliative, but focused on the underlying disorder. 
 The behavioral-pharmacologic hypothesis approach is based on the notion that there may be 
specific mechanisms that explain the probable genesis and maintenance of a target behavior 
(Conner, 2002; Rush & Francis, 2000).  For example, aggression (e.g., self-injury) may occur as a 
result of an imbalance of endogenous opiates in the body and using naltrexone to restore this 
imbalance will reduce or eliminate the aggression. 
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 PREVALENCE OF PSYCHOTROPIC MEDICATION USE 
 In 1966, Ronald Lipman undertook the first survey of drug usage among individuals with 
mental retardation in institutions.  This seminal investigation examined 142 state and 31 private 
institutions across the country and found that 51% of residents were prescribed psychotropic 
medications.  Interestingly, two drugs, specifically thioridazine and chlorpromazine, accounted for 
approximately 58% of all psychotropic drug prescriptions and were the two most frequently 
prescribed drugs in 91% of the institutions surveyed (Lipman, 1970).   Overall, the drug classes that 
were prescribed most commonly were major tranquilizers, which accounted for 39.2% of 
prescriptions, minor tranquilizers (8.1%), and antidepressants (3.8%).  Further, in the institutions 
surveyed, 25% of the residents’ prescribed psychotropic medications typically received these drugs 
for four years up to an indefinite period of time.  While this survey did not examine the issue of 
polypharmacy, the prescription of two or more psychotropic medications, Lipman (1970) did find 
that maximum dosages above recommendations set by drug manufacturers were common. 
 This landmark study was followed by several other investigations, with most reporting 
similar findings (Singh, Ellis, & Wechsler, 1997).  In an effort to update Lipman’s survey Singh, Ellis, 
and Wechsler (1997) reviewed drug prevalence studies between 1966 and 1995.  This review split the 
sample of drug prevalence studies into two time periods, one from 1966 to 1985 and the other from 
1986 to 1995.  Research performed from 1966 to 1985 had been summarized by other authors, so 
Singh et al. (1997) only briefly summarized previous findings.  During the first time period, 1966 to 
1985, the prevalence of psychotropic drug use in institutions ranged from 19% to 86% with most 
studies reporting between 30% and 50%.  In the community samples, the prevalence of 
psychotropic drug use in adults ranged from 26% to 36%.  During the second time period, 1986 to 
1995, Singh et al. found that the prevalence of psychotropic drug use in institutions ranged from 
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 12% to 49%.  In community studies, the typical prevalence rate of psychotropic drugs ranged from 
19% to 29%. 
 Since the Singh et al. (1997) review, several studies have been published which examine the 
prevalence rates of psychotropic medication use among individuals with mental retardation and have 
reported similar findings (e.g., Nottestad & Linaker, 2003; Roberson et al., 2000; Stolker, Koedoot, 
Heerdink, Leufkens, & Nolen, 2002).  The prevalence of psychotropic drug use in institutions has 
been found to range from 25% to 60% (Roberstson et al., 2000).  In community settings, the 
prevalence rate of psychotropic medication use has been found to range from 20% (Emerson et al., 
1997) to 56% (Roberstson et al., 2000). 
 As the literature demonstrates, there has not been a significant change in the use of 
psychotropic medications among individuals with developmental disabilities since Lipman’s survey 
in 1966.  This situation is surprising considering the emergence of literature indicating that the use of 
such medication in this population is often unnecessary and inappropriate.  Further, research has 
shown that most of the medications being prescribed to individuals with developmental disabilities 
can have serious side effects and cause long term harm.  While guidelines for the prescription of 
psychotropic medications exist (e.g., American Journal on Mental Retardation, Vol. 105, No. 3; Reiss 
& Aman, 1998) the prevalence of these medications suggests that these guidelines are not be being 
followed and individuals with mental retardation may be overmedicated.  
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 PSYCHOTROPIC MEDICATIONS 
 Psychotropic medications affect specific brain functioning by increasing or decreasing the 
activity of neurotransmitters, the chemical messengers of the brain (Diamond, 2002).  Some 
neurotransmitters trigger the firing of nerve cells and are known as excitatory while others block the 
firing of a nerve cell and are known as inhibitory.  Medications are designed to either increase or 
decrease the activity of specific neurotransmitters.  Change in the neurotransmitter pathways cause 
changes in brain functions that ultimately lead to changes in an individual’s behavior.  As previously 
noted, psychotropic medications are used to target behavioral and psychiatric symptoms of mental 
illness. 
History 
 The historical origin of the antipsychotic known as Chlorpromazine (CPZ) dates back to 
1883 and the synthesis of its parent compound phenothiazine by a German chemist named August 
Heinrich (Swazey, 1974).  Interestingly, Heinrich was investigating the structural properties of 
methylene blue compounds, valuable dye products.  In 1883 he published a paper in which he 
described the nucleus of methylene blue and its synthesis; the nucleus he described was 
phenothiazine.  The identification of and synthesis of methylene blue would have effects far beyond 
the dye industry (Swazey, 1974). 
The advent of CZP in 1950 was the result of the combination of two lines of research.  One 
line was concerned with the production of synthetic antihistamines that were powerful and nontoxic 
enough to be used in the treatment of allergies.  The other was phenothiazine chemistry that was 
aimed at creating drugs that could be used to fight malaria, African sleeping sickness, and worm 
infestations.  In 1945, these lines of research merged when chemists at the French laboratory 
Rhone-Poulenc discovered that a phenothiazine amine compound named 3015 RP, synthesized by 
Paul Charpentier, had strong antihistamine properties (Swazey, 1974).  Research into phenothiazine 
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 amines was further advanced in 1946 when it was reported to be useful in the treatment of 
Parkinson’s disease.  These clinical effects of the phenothiazine amine, namely sedation, led 
researchers to believe that these drugs had some type of unknown central nervous system effects. 
Concurrent with the research being conducted at Rhone-Poulenc, French navy surgeon 
Henri Laborit was using synthetic antihistamines to fight circulatory shock after surgery.  While 
using antihistamines, Laborit noted secondary qualities beneficial to the prevention and treatment of 
surgical shock: hypothermic and gangliopalegic properties.  This, coupled with other clinical findings 
were factors in Rhone-Poulenc’s decision to begin research into the development of a phenothiazine 
amine that displayed a high degree of central nervous system activity regardless of it antihistaminic 
activity (Koetschet, 1955).  In 1950, Rhone-Poulenc began intensive studies of CPZ’s 
pharmacological properties; the results of these initial studies indicated strong central action and 
clinical trials. 
Laborit, who wanted an alternative to the drug he was using at the time, began using CPZ to 
relax patients and reduce the likeliness of surgical complications and shock.  He reported that 
patients who received 50-100 mg intravenously had some drowsiness but were indifferent to the 
surgical procedure; in fact, he reported that his patients had a broader indifference and seemed not 
to care about anything at all (Laborit, Huguenard, & Alluaume, 1952).  Labroit’s results led him to 
suggest to a number of psychiatrists that the use it with psychiatric patients.  However, not many of 
his colleagues were interested. 
CPZ’s efficacy as an antipsychotic was not clinically established until 1952.  Until this time, a 
small series of publications had been reporting the use of CPZ in French psychiatric patients, with 
some success.  These papers showed that CPZ was being used in four major ways: 1) as a barbiturate 
potentiator in manic agitation; 2) in conjunction with shock treatment in anxiety states and manic 
depressive states; 3) the potentiation of other drugs in sleep therapy; and 4) administered alone.  It 
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 was this last area of research, used alone, that is historically the most significant (Swazey, 1974).  In 
1952, John Delay and Pierre Deniker presented a report to the Societe Medico-Psychologique that, 
while not a permanent cure, CPZ was effective in reducing manic states in psychiatric patients 
(Delay & Deniker, 1952).  This report is often cited as being the first public presentation of an 
effective drug treatment for a mental disorder (Marder & Van Putten, 1995). 
News of this discovery spread quickly, and within two years CPZ was used around the world 
to help individuals with agitation associated with mania and nausea.  CPZ’s rapid and widespread 
increase in usage can be attributed to several factors.  The foremost of which was that until CPZ, 
there was no other effective treatment for schizophrenia or any other form of psychosis (Marder & 
Van Putten, 1995).  Another factor was that CPZ was inexpensive to administer and was considered 
relatively safe, despite it side effects.  Further, CPZ was effective for a large number of individuals, 
leading to a decrease in the use of restraint devices, seclusion, and locked units.  Unfortunately, 
many individuals have residual symptoms and continue to relapse. 
 However, the advent of CPZ for use in psychiatric populations was not the only 
precipitating factor to spark research into the biological basis of psychotic disorders and drug that 
could be used to treat them.  Several decades’ earlier, Indian researchers began scientific 
investigations of R. serpentina, a tropical species of shrub that grows in regions of India.  In the 
early 1930’s, researchers isolated several of R. serpentina’s alkaloids and began documenting their 
physiological activity and noted that the compound was useful in treating violent manic symptoms 
associated with insanity (Baumeister & Francis, 2002).  Shortly after the publication of these results, 
Ciba laboratories identified the sedative aspect of R. serpentina, which they named reserpine and 
marketed as an antihypertensive-sedative called Serpasil.  (Baumeister, Hawkins, & Uzelac, 2003).  
Clinical trials soon established that the clinical profile of reserpine was close to that of CPZ, that is, 
both drugs were sedating without producing a clouding of consciousness as found in barbiturates 
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 (Swazey, 1974).  These new drugs were labeled neuroleptics, a term arising from the Greek works 
neuron and leptos meaning to “take hold of the nervous system” (Deniker, 1983). 
 While the discovery of CPZ was paramount in the beginning stages of psychopharmacology 
and neuroleptic drug development, it was not a cure all and not without problems.  Shortly after 
CPZ’s introduction in 1952, side effects that included induced Parkinsonism and other 
extrapyramidal side effects (EPS), such as tardive dyskinesia, were being reported (Lehmann & 
Hanrahan, 1954).  The ability of neuroleptic drugs to produce antipsychotic as well as extrapyramidal 
effects has been attributed to their ability to block the D2 dopamine receptor subtype.  Because 
typical antipsychotics often do not result in a full remission of symptoms and produce unwanted 
side effects, researchers have been searching for better antipsychotic drugs.  Researchers have been 
focusing on compounds with an improved efficacy on both positive symptoms (an excess or 
distortion of normal functioning such as delusions, hallucinations, and disorganized speech) and 
negative symptoms (restrictions in the range and intensity of emotional expression, fluency and 
productivity of speech and thought, and initiation of goal oriented behavior) and side effects profiles 
(APA, 2000; Owens & Risch, 1995). 
Second-generation antipsychotics have been termed atypical, as they tend to produce fewer 
extrapyramidal side effects and improved efficacy at therapeutic doses (Owens & Risch, 1995).  
While unclear, the mechanism of action of the atypical drugs is considered to be through either 
differential actions in various dopamine neurons and/or binding to different dopamine receptor 
subtypes, or additional binding to other neurotransmitter receptors (Owens & Risch, 1995).  Studies 
have shown atypical drugs to be relatively weaker D2 antagonists and that they possess relative 
mesolimbic dopaminergic specificity compared to nigrostriatal dopamine neurons.  This selective 
targeting may explain why atypical antipsychotics have fewer EPS side effects and tardive dyskinesia 
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 liability.  Six second-generation atypical antipsychotic medications have been introduced since the 
late 1980’s and include olanzapine, risperidone, sertindole, and ziprasidone. 
 Clinically, neuroleptics are generally effective in controlling psychomotor agitation and 
excitement, in the management of psychosis, and the treatment of schizophrenia and mania 
(Lieberman & Mendelowitz, 2000).  Antidepressants are useful in the treatment of depressive 
disorders and anxiety disorders such as obsessive-compulsive and panic disorders (Ban, 2001).  
Minor tranquilizers relieve tension and are used to treat panic attacks and generalized anxiety 
disorder, and hypnotics-sedatives are used in the treatment of insomnia (Diamond, 2002).  Mood 
stabilizers are used to treat manic-depressive and bipolar disorders (Hopkins & Gelenberg, 2000).  
Stimulant medications are used to treat attention deficit hyperactivity disorder and narcolepsy 
(Fawcett & Busch, 1995).  Cholinesterase inhibitors have shown promise in the treatment of 
Alzheimer’s disease (Ban, 2001). 
Determining which medication is best suited for an individual is a complex task.  To aide 
clinicians in this task, several expert consensus guidelines have been developed (Rush & Frances, 
2000; Reiss & Aman, 1998), along with medication algorithms such as the Texas Medication 
Algorithm Project (Gilbert et al., 1998; Rago & Shon, 2001).  These guidelines and algorithms 
provide clinicians with step-by-step procedures for the implementation of medication regimens 
based on the characteristics of an individual and their presenting symptomology.  In addition, they 
provide clinicians with alternative drug therapies if the first line does not have a significant positive 
impact.  Therefore, these guidelines also serve to inform clinicians about the multiple uses and 
combinations of various medications to safely reach a desired therapeutic effect and how to 
effectively monitor their clients progression.  The following is a review of the most common classes 
of medications shown to be useful among individuals with mental retardation including drug 
mechanisms, clinical effects, and side effects. 
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 Antipsychotic Medications 
Antipsychotic drugs are used to treat nearly all forms of psychosis and psychoses associated 
with organic mental disorders (Marder & Van Putten, 1995).  First generation antipsychotics are 
classified as a neuroleptic; a term arising from the Greek works neuron and leptos, meaning to “take 
hold of the nervous system” and used to describe the adverse motor slowing effects of these drugs 
(Lieberman & Mendelowitz, 2000).  The implication was that the motor side effects were a 
fundamental part of the therapeutic aspects of the drugs and could not be separated out.  Thus, 
typical antipsychotic drugs developed until the late 1980’s were considered to be neuroleptics.  
However with the introduction of clozapine, the first of the second-generation medications to have 
antipsychotic properties without EPS, the term neuroleptic was no longer appropriate (Lieberman & 
Mendelowitz, 2000).  As such, second-generation neuroleptics were termed atypical antipsychotics.  
Although drug classes are based on biochemical structure, a more meaningful classification within 
antipsychotic medications is whether they are EPS-producing neuroleptics or non-EPS-producing 
antipsychotics (Stahl, 1996). 
Mechanism 
The traditional, or older, typical antipsychotic medications typically exerted their effects by 
blocking the D2 dopamine receptor in the brain.  There are four major dopamine pathways in the 
brain and typical antipsychotics block all four of these pathways.  However, the dopamine pathway 
located in the limbic system, specifically the mesolimbic dopamine pathway is considered 
responsible for psychotic symptoms.  Generally, chemicals that decrease activity in this pathway 
decrease psychotic symptoms while chemicals that increase activity increase, or cause, psychotic 
symptoms (Diamond, 2002).  Another dopamine pathway located in the frontal cortex that 
stimulates behavior, thought, expression, and motivation is the mesocortical dopamine pathway.  
Blocking dopamine in this pathway decreases these aspects of an individual’s personality and can 
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 exacerbate the negative symptoms of schizophrenia.  The third dopamine pathway is located in the 
nigrostrital pathway, an area responsible for the control of the extrapyramidal motor system.  
Blocking dopamine in this pathway causes a loss in voluntary muscle movement resulting in 
parkinsonism-like extrapyramidal side effects (EPS) (Stahl, 1996).  The fourth pathway is the 
tuberoinfundibular dopamine pathway responsible for the secretion of prolactin, a sex-related 
hormone produced by the hypothalamus.  When this pathway is blocked, the individual’s prolactin 
level increases and can result in breast enlargement, secretion of a milk-like substance from the 
breasts in both men and women, and other sexual side effects.  As the typical antipsychotics are not 
selective with respect to which pathway dopamine is blocked. 
 New atypical antipsychotic medications leave dopamine receptors in other parts of the brain 
largely unaffected by using the brain’s own self-regulation system (Diamond, 2002).  One hypothesis 
is that serotonin blocks the release of dopamine in some brain pathways.  As such, blocking 
serotonin receptors causes nerve cells to release more dopamine.  If both serotonin and dopamine 
receptors are blocked at the same time, the result is a net increase in the amount of dopamine 
released.  However, as only some of the dopamine receptors are blocked, the dopamine system is 
less sensitive to the increased amount of dopamine and the overall response to dopamine remains 
about the same.  Thus, the increased amount of dopamine released has relatively no effect in those 
areas that have a serotonin control system.  Interestingly, there is no serotonin control system in the 
mesolimbic dopamine pathway, the pathway responsible for the expression of psychotic symptoms.  
By blocking dopamine and serotonin at the same time, atypical antipsychotic medications selectively 
block dopamine in only one part of the brain.  However, reaching a balance between blocking 
serotonin and dopamine is not easy and there is more than one type of serotonin receptor. 
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 Side Effects 
 All antipsychotic medication side effect profiles can be grouped into four broad categories: 
1) muscle related, or extrapyramidal, 2) non-muscle related, 3) dangerous or rare, and 4) weight gain 
and diabetes.  These categories represent a wide range of potential side effects that correspond to 
each drugs pharmacological properties (Lieberman & Mendelowitz, 2000).  Further, typical and 
atypical antipsychotic medications vary widely in their side effect profiles both between and within 
each drug classification. 
 All of the typical antipsychotic medications reduce psychotic symptoms by blocking 
dopamine receptor sites in the brain.  However, each of the typical antipsychotic medications varies 
in potency.  That is, different amounts of each medication are required to be equally effective.  High 
potency medications are relatively less sedating, cause less postural hypotension, and cause fewer 
anticholinergic side effects such as blurred vision, constipation or dry mouth (Stahl, 1996).  
However, high potency typical antipsychotic medications also have a higher incidence of 
extrapyramidal side effects (EPS) such as tremors, motor restlessness, and tardive dyskinesia.  New 
atypical antipsychotic medications also produce extrapyramidal side effects but with far less 
incidence and severity than the typical antipsychotic medications. 
The first category of side effects is extrapyramidal effects.  Pyramidal nerve cells are those 
cells in the brain that control voluntary muscle movement.  Extrapyramidal refers to those areas in 
the central nervous system that are not part of the main pyramidal tract and are concerned with 
control and coordination of muscle movements.  While not typically dangerous, this category of side 
effect is uncomfortable and cause many individuals to discontinue the use of their antipsychotic 
medication.  Most of the EPS’s, with the exception of tardive dyskinesia and akathisia, are usually 
treatable with other medications such as anticholinergic agents and disappear with the 
discontinuation of the antipsychotic medication.  Each EPS has a time course, except for tardive 
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 dyskinesia) and may not require medication treatment.  Tardive dyskinesia, a set of hyperkinetic 
movements that especially effects the face, neck, and extremities and can include movements such as 
lip smacking, chewing, tongue protrusions, facial grimacing, and rapid limb movements has no 
reliable treatment and persist even after antipsychotic medication is stopped.  Other EPS’s include 
dystonia; sudden spasms of the muscles in the head, neck, lips, and tongue; pseudoparkinsonism, 
which consists of muscular rigidity, mask-like face, and a stiff walk; akathisia, characterized by 
constant pacing, moving of hands and feet, and a feeling of nervousness; and akinesia, manifested by 
a loss of spontaneity in facial expression or gesturing, decreased social spontaneity, diminished 
conversation, apathy, and disinclination to initiate normal activity. 
 Common, non-muscle related effects are a second broad category of side effects seen in 
antipsychotic medications.  This category includes effects such as, depression, depersonalization, 
akinesia, confusion, somatic delusion, and dysphoria.  These side effects are seen more in the typical 
antidepressants (Diamond, 2002).  Anticholinergic side effects such as dry mouth, blurred vision, 
and constipation are also included in this category.  As anticholinergic medications block the 
sweating response, temperature regulation problems are another common set of side effects.  Most 
of the anticholinergic side effects seen actually come from the medications used to treat the muscle 
related side effects of the antipsychotic medications, such as cogentin, donepezil, galantamine, and 
rivastigmine (Tammenmaa, McGrath, Sailas, & Soares-Weiser, 2004).  Another set of non-muscle 
related side effects are alpha-adrenergic.  These include orthostatic hypotension, a sudden drop in 
blood pressure when an individual stands up and transient dizziness.  Again, these side effects are 
seen more in typical antipsychotics.  However, in atypical medications the effects are worse with 
clozapine and risperidone.  As antipsychotic medications block the D2 receptor they cause an 
increase in prolactin, again seen more with typical antipsychotic medications.  This can result in 
breast enlargement, secretion of breast liquid from men and women, interference with menstrual 
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 periods in women, and a decreased sex drive.  Photosensitivity is another side effect caused by 
antipsychotic medications. 
Antidepressant Medications 
 The discovery of the antipsychotic properties of chlorpromazine began the revolution in the 
pharmacological treatment of psychosis.  Similarly, the accidental discovery of the antidepressant 
properties of the antituberculosis drug iproniazid revolutionized the treatment of depression in the 
1950’s (Mendelowitz, Dawkins, & Lieberman, 2000).  Until this time no effective antidepressants 
existed.  In the early 1950’s it was noted that a side effect of iproniazid was euphoria.  This 
observation led to clinical trials during which it was discovered that iproniazid was useful for 
tuberculosis patients with depression (Crane, 1957).  Another accidentally discovered antidepressant 
was imipramine, which was originally developed as a potential antipsychotic.  However, during 
clinical trials it was noted that imipramine elevated mood in individuals with schizophrenia.  This 
discovery led to effective trials with individuals with depression (Kuhn, 1958).  Both of these 
medications have different mechanisms of action.  Iproniazid’s therapeutic efficacy involves the 
inhibition of the enzymes that degraded monoamines, which in turn increase norepinephrine, 
serotonin and dopamine activity.  However, Imipramine’s mechanism of action involves blocking 
the reuptake of serotonin and norepinephrine.  Thus, there are at least two neurotransmitters 
responsible for depression: serotonin and norepinephrine.  However, it is not fully understood how 
antidepressant medications work.  What is known is that all effective antidepressants interact with 
one or more neurotransmitter receptors or enzymes (Stahl, 1996). 
Mechanism 
 The theoretical mechanism of action of antidepressant medications involves the serotonergic 
and catecholaminergic systems in the central nervous system (Mendelowitz et al., 2000).  There are 
four classes of antidepressant medications: (1) the monoamine oxidase inhibitors (MAOIs), (2) 
 18
 tricyclic antidepressants (TCAs), (3) selective serotonin reuptake inhibitors (SSRIs) and (4) 
serotonin-norepinephrine reuptake inhibitors (SNRIs). 
 The first clinically effective antidepressants were drugs that inhibited the monoamine oxidase 
enzyme and were accidentally discovered while researchers were searching for an antituberculosis 
drug.  When the antituberculosis drug was given to tuberculosis patients the drug was observed to 
help their depressive symptoms.  As is had already been discovered that the antituberculosis drug 
inhibited the monoamine oxidase (MAO) enzyme, it was hypothesized that this biological event 
accounted for the drugs antidepressant effects.  The MAO enzyme is responsible for breaking down 
monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine thereby 
functionally decreasing the levels of these neurotransmitters (Janicak et al., 1993).  All of the original 
MAOIs are irreversible enzyme inhibitors that bind to, and destroy, the monoamines in the 
cytoplasm.  The effects of the MAOIs continue for 10 to 14 days after their used has been 
discontinued, until new MAO enzymes can be synthesized.  MAOIs are beneficial in the treatment 
and management of atypical depression, mixed anxiety and depressive disorders. 
 MAO has two subtypes, A and B.  Subtype A metabolizes serotonin and norepinephrine, the 
monoamine neurotransmitters most closely linked to depression (Stahl, 1996).  The subtype B 
enzyme is believed to metabolize dopamine and phenylethlamine into toxins that may damage 
neurons.  Inhibiting the B form of MAO is linked to the prevention of some neurodegenerative 
processes such as those found in Parkinson’s.  All of the original MAOIs inhibited both of these 
subtypes and were therefore nonselective.  However, in recent years, new MAOIs have been 
produced that selectively inhibit MAO A or MAO B.  Further, for MAO A’s, the new drugs are 
reversible and are therefore called reversible inhibitors of MAO A (RIMAs).  A new RIMA, 
Moclobemide, is now available in Canada and the United Kingdom.  However, is not yet in the 
United States (Mendelowitz et al., 2000). 
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  Tricyclic antidepressant (TCAs) medications are so named because of their organic three-
ring molecular structure.  The results of clinical trials were disappointing and TCAs were almost 
discarded.  However, researchers noted that TCAs helped relieve some of the depressive symptoms 
in patients with schizophrenia who had comorbid depression.  It was not until later that researchers 
discovered TCAs worked by blocking the presynaptic reuptake of norepinephrine and serotonin, 
and, to some degree, dopamine.  In addition to these effects, to some degree all TCAs block 
muscarinic cholinergic, H1 histamine, and alpha 1 adrenergic receptors (Stahl, 1996).  The 
therapeutic antidepressant effects of TCAs are thought to be due to the blockage of serotonin and 
norepinephrine reuptake, while the blockade of these other three-receptor systems are responsible 
for the TCAs side effects.   
 TCAs modulate the reuptake of neurotransmitters to various degrees.  Older TCAs, such as 
imipramine and amitriptyline, the tertiary amines, are metabolized into secondary amines by hepatic 
enzymes.  The tertiary amine TCAs have a greater effect at blocking the reuptake of serotonin than 
do the secondary amines which are more effective at blocking the reuptake of norepinephrine.  
More importantly, these TCAs have differing clinical effects.  Secondary amine TCAs are less likely 
to interact with other receptors, as such, the side effect profiles of the secondary amines are 
improved over the tertiary amines.  All TCAs are considered to be nonselective in that each blocks 
the reuptake of monoamines.  However, they also interact with a wide variety of other 
neurotransmitter receptor systems (Mendelowitz et al., 2000). 
 The second generation of antidepressant medications selectively blocks the reuptake of one 
neurotransmitter receptor system, usually serotonin.  This new generation of antidepressants is 
known as selective serotonin reuptake inhibitors (SSRIs) as they effectively block the reuptake of 
serotonin while having little effect on adrenergic, histaminergic, or cholinergic receptor systems.  
Functionally, all SSRIs increase the amount of serotonin available in the synapse.  Increased 
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 serotonin at receptor sites has, for some individuals, the therapeutic effect of relieving some of the 
symptoms of depression. 
 One of the newest second-generation antidepressant medications being developed are 
serotonin-norepinephrine reuptake inhibitors (SNRIs).  SNRI drugs, such as venlafaxine, share the 
inhibitory reuptake properties of the classical TCAs.  However, they do not effect the adrenergic, 
histaminergic, or cholinergic receptor systems and thus have different therapeutic and side effect 
profiles.  The blocking properties of venlafaxine are dose dependant; it is most effective in blocking 
serotonin and at low doses, norepinephrine at higher doses, and dopamine at the highest doses.  
Although SNRIs are clinically effective as antidepressants, it remains unclear whether or not they 
have advantages over SSRIs in terms of efficacy or side effect profile (Stahl, 1996).   
Side Effects 
 The use of MAOIs in the United States has begun to decline in recent years.  This is 
primarily due to the need for dietary restrictions and the potential for serious side effects 
(Mendelowitz et al., 2000).  The most common long-term side effects of MAOIs are weight gain, 
edema, muscle twitching, and decreased sexual functioning.  Other side effects of MAOIs include 
anticholinergic effects such as blurred vision, dry mouth, urinary hesitancy, constipation, behavioral 
problems, and memory impairment.  A less common but more serious side effect of MAOIs is a 
hypertensive crisis caused by the interaction of the MAOI with tyramine found in food or a 
medication that contains a sympathomimetic amine, amines that have an effect on the sympathetic 
nervous system.  MAOIs work by interfering with the enzymes that break down neurotransmitters.  
However, some of these enzymes also break down tyramine.  Therefore, tyramine levels can increase 
to high levels and cause an increase in blood pressure.  The hypertensive crisis is usually preceded by 
a sudden increase in blood pressure, headache, stiff neck, and vomiting (Maxmen & Ward, 2002).  
While rare, the hypertensive crisis may be fatal and requires immediate treatment.  Besides a wide 
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 range of foods, MAOIs also interact with a large number of medications, including many over-the-
counter medications and other antidepressants.  Further, MAOIs have an activating effect that may 
result in manic episodes, psychosis, behavioral outbursts, loss of sleep, and decreased attention. 
 NDRIs are effective antidepressants and are reported to have fewer side effects than the 
older antidepressant medications, because they do not affect serotonin systems.  One of the major 
advantages of NDRIs is that they do not cause any sexual side effects; in fact, it can actually reverse 
the sexual side effects of other antidepressant medications (Diamond, 2002).  As with MAOIs, 
NDRIs are also activating and thus cause side effects such as restlessness and sleep problems.  
However, the occurrence of these side effects is less than with MAOIs.  Rare side effects of NDRIs 
include nausea and slight tremors.  Unfortunately, NDRIs have an increased risk of grand mal 
seizure than most other antidepressants (Stahl, 1996).  This risk is dose related and increases as the 
dosage of the NDRI increases. 
Tricyclic antidepressant medications, although older, are just as clinically effective as the new 
antidepressant medications.  However, the major problem is that TCAs are much more dangerous 
especially when taken as an overdose; a month’s worth of any TCA is lethal if taken all at once.  
Individuals taking TCAs typically feel drugged and sedated more than with the newer 
antidepressants.  As TCAs block the muscarinic cholinergic, H1 histamine, and alpha 1 adrenergic 
receptors, they have many more side effects that most of the newer, selective antidepressant 
medications (Mendelowitz et al., 2000).  The anticholinergic properties of TCAs cause side effects 
such as dry mouth, blurred vision, heart palpitations, urinary retention, confusion, and delirium 
while blockage of the histamine receptors causes sedation and weight gain.  Blocking the adrenergic 
receptors creates one of the TCAs most frequent and limiting side effects, orthostatic hypotension, 
the sudden loss of blood pressure, and cardiac arrhythmias due to the inability of electrical impulses 
in the heart to spread normally (Diamond, 2002).  While rare, these cardiac complications have been 
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 reported to cause death.  TCAs also potentiate the effects of alcohol and individuals who drink while 
on TCAs may become more intoxicated than usual.  Further, TCAs increase the lethality of alcohol 
and put the individual at risk for overdose.  Other side effects of TCAs are loss of sexual function, 
manic episodes, allergies, nightmares and seizures. 
The advantage of the SSRIs is that they are much safer and better tolerated than the older 
antidepressant medications.  This is because the SSRIs only selectively inhibit the reuptake of 
serotonin and have little, if any, interaction with histaminergic, muscarinic, or alpha-adrenergic 
receptors.  Thus, the side effect profiles seen in the SSRIs are caused by the blockage of serotonin 
reuptake.  As such, while not significantly more effective than older and other antidepressants, 
SSRIs are becoming more widely used because of the fewer side effects they cause.  Some of the 
common side effects caused by SSRIs are nausea, vomiting, anorexia, tremors, initial weight gain, 
and diarrhea.  However, most of these are dose dependent and can be lessened by titrating the 
medication more slowly and having the individual take the medication with food (Mendelowitz et al., 
2000).  Like some of the other antidepressants discussed earlier, SSRIs tend to be activating, thus 
some individuals feel agitation, restlessness, and some sleep disturbance. Further, some SSRIs such 
as fluoxetine (Prozac) cause akathisia, a type of motor restlessness.  Also, some individuals feel an 
emotional blunting.  Although most antidepressants cause some degree of sexual dysfunction, the 
incidence of sexual dysfunction in SSRIs is more common (Janicak et al., 1993).  These side effects 
include decreased libido, anorgasmia in women and delayed ejaculation in men. 
SSRIs also interact with other medications in dangerous ways by blocking their metabolism 
in the liver (Diamond, 2002).  By blocking the break down of other drugs, SSRIs can cause the levels 
of other medications to rise to toxic levels.  Specifically, SSRIs interfere with a set of enzymes in the 
liver called the P450 system.  To complicate matters, different SSRIs interfere with different 
enzymes in the P450 system, thus different SSRIs interact with different medications to cause 
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 different problems.  SSRIs also interact with many medications used to treat HIV.  Research shows 
that individuals taking HIV medication should only be prescribed ¼ to ½ of the normal dose 
(Diamond, 2002).  The most dangerous and common interaction between SSRIs and other 
medications occur when the individuals is also taking an MAOI antidepressant.  This combination, 
the SSRI and an MAOI, can result in serotonin syndrome whose symptoms include agitation, 
confusion, sweating, increased reflexes, sudden jerking movements, shivering, tremors, coordination 
problems, and fever. 
Mood-Stabilizing Medications 
 The discovery of medications that could stabilize an individual’s mood dates back to the late 
1940’s.  The first drug used as an anti-manic was lithium that had been used in medicine since the 
mid-19th century to treat a variety of disorders such as diabetes, gout, rheumatism, and urinary 
calculi.  During the early 1940’s it was used as a salt substitute for cardiac patients.  However, lithium 
caused a number of toxic reactions and deaths (Janicak et al., 1993).  Then in late 1949, John Cade, 
an Australian physician injected lithium urate into guinea pigs.  Cade mistakenly took the toxic 
effects of lithium as sedating and, based on this, ran a successful open trial of lithium with manic 
patients.  In 1954, Mogens Schou used lithium in a series of methodologically rigorous studies that 
demonstrated its efficacy in stabilizing both phases of bipolar disorder and preventing recurrences of 
unipolar depressive disorder in patients (Schou, Juel-Neilson, Stromgren, & Voldby, 1954).  After 
lithium’s anti-manic properties were discovered, a series of studies were conducted that replicated 
Cade’s initial findings.  While these studies demonstrated lithium’s usefulness, they also revealed that 
lithium was still toxic and lethal when used as an anti-manic.  It was not until the 1960’s when 
Samuel Gershon reintroduced lithium as a viable treatment for mania that it became the standard 
therapy for bipolar disorder and was approved for use in the United States in 1970 (Hopkins & 
Gelenberg, 2000).   
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 However, recent research has begun to acknowledge that a significant proportion of patients 
cannot tolerate or do not benefit from lithium therapy (Janicak et al., 1993).  Individuals who do not 
seem to respond to lithium include those that present with dysphoric and mixed episodes of mania, 
rapid cycling, a history of neurological disease, and comorbid substance abuse (Hopkins & 
Gelenberg, 2000).  This has led to investigations into alternative treatments such as 
electroconvulsive therapy (ECT) and antiepileptics.  The most common antiepileptics used to treat 
mania in patients that are unresponsive to lithium are valproate (VPA) and carbamazepine (CBZ).  
As with most of the other psychotropics, the anti-manic properties of antiepileptic medications, 
specifically CBZ, were discovered by accident.  In the 1960s, researchers were studying the effects of 
CBZ in epileptic patients and noted that it also had anti-aggressive properties (Dehing, 1968).  While 
VPA is approved for the acute care of mania, this section will focus on the mechanism and side 
effects of lithium as used as a mood stabilizer.  VPA and CBZ will be discussed further in the 
antiepileptic section along with other antiepileptic medications that are currently being researched 
for their anti-manic properties. 
Mechanism 
 While many of lithium’s effects on the body are known, the exact mechanism that is 
responsible for its mood stabilizing properties are not fully understood, although several theories 
have been postulated (Viesselman, 1999).  One theory is that it affects those neurotransmitter 
systems implicated in affective disorders, norepinephrine, acetylcholine, serotonin, and dopamine.  
Lithium has a variable effect on norepinephrine by inhibiting its release and seems to enhance 
acetylcholine function.  Its antidepressant effects may be due to its enhancement of serotonin 
activity and its anti-manic properties are thought to be due to its prevention of dopamine receptor 
super sensitivity and inhibition of its release (Hopkins & Gelenberg, 2000). 
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  Another theory is that lithium affects cellular processes, specifically affecting second-
messenger G-protein systems and signal-transduction systems.  A third theory is that lithium alters 
neuron functioning by substituting or competing with other ions, as it shares properties with 
potassium, sodium, magnesium, and calcium, and altering their distribution throughout the body.  A 
fourth theory is that lithium may modulate the interaction between several neurotransmitters and act 
as a neuromodulator and balance various neurotransmitter systems.  Research continues to 
determine the exact nature of lithium’s therapeutic effects as a mood stabilizer. 
Side Effects 
 Lithium produces a wide variety of side effects, some of which the individual may become 
tolerant of and others that may warrant the use of adjunctive or alternative therapies.  The most 
common side effect of lithium is fine tremor of the hands during the first few days of treatment 
(Stahl, 1996).  Other initial side effects of lithium are nausea, vomiting, abdominal pain, thirst, and 
fatigue.  However, most of these disappear after the first few weeks of treatment.  Other reported 
side effects include mild weight gain, a metallic taste in the mouth, headache, memory and 
concentration difficulties, dermatitis, and polyuria (Maxmen & Ward, 2002).  Lithium is also known 
to affect thyroid function by inhibiting several steps of thyroid hormone synthesis and degradation 
resulting in hypothyroidism.  As the kidney excretes lithium, it also has a direct effect on renal 
functioning and may cause a syndrome called nephrogenic diabetes insipides characterized by 
increased fluid intake and urination.  However, very few individuals who receive long-term lithium 
therapy suffer permanent, life-threatening kidney damage.  Lithium has a low therapeutic index, and 
increased blood concentrations can cause eventual coma or death (Stahl, 1996).  The initial 
symptoms of lithium toxicity look like more severe presentations of common lithium side effects 
such as thirst, decreased appetite, diarrhea, and vomiting.  These symptoms can progress to tremors, 
confusion, slurred speech, and muscle twitching.  If left untreated, the toxic lithium blood levels can 
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 cause permanent central nervous system damage, increased reflexes, renal shutdown, seizures, 
permanent brain damage, coma, and possible death. 
Antianxiety Medications 
 The discovery of antianxiety medications, also known as anxiolytics, did not have an 
accidental beginning like most other psychotropics.  The use of anxiolytics can be traced back 
centuries to alcohol and its progression can be followed from there to the use of opiates to the 
synthesis of bromides and barbiturates to the formulation of benzodiazepines in the 1960s (Janicak 
et al., 1993).  All of these medications have similar affects; they all have antianxiety and sedative 
properties caused by depression of the central nervous system.  The earliest treatment for general 
anxiety was barbiturates, which were highly sedating.  In fact, the antianxiety effect of barbiturates 
was directly proportional to its sedating affect, thus its effects were not anxiety specific.  That is, 
these drugs reduced anxiety by inducing sedation.  Also, this class of antianxiety medication had 
some serious problems such as dependency and withdrawal effects, and safety concerns when 
combined with other medications or in overdose.  Barbiturates were supplanted when 
benzodiazepines, a new class of antianxiety medication, were discovered.  These new drugs had 
fewer problems, were effective in a wider range or disorders, safe with most other medications, and 
caused less sedative effects than barbiturates (Diamond, 2002).  For the first time, selective 
antianxiety effects were observed.  Benzodiazepines were hailed as a breakthrough and remain 
among the most widely prescribed drugs in the world.  Recently, a new class of anxiolytic drug has 
been formulated called azapirones that are not chemically related to barbiturates or benzodiazepines 
and affects different neurotransmitter systems.  Currently, buspirone is the only azapirone indicated 





 All benzodiazepines are comprised of a 6-member benzene ring fused to a 7-member 
diazepine ring, and thus get their name from their chemical structure.  The different 
pharmacokinetic properties seen within benzodiazepines results from different substitutions on the 
diazepine ring in different positions; therefore, each structure differs in potency, duration of action, 
and the type and frequency of side effects (Janicak et al., 1993).  The wide diversity in therapeutic 
and side effect profiles of the different benzodiazepines is due to the speed of onset of action, 
potency, and the half-life of the specific medication.  These factors allow for the selection of specific 
medications to fit the needs of the individual.  However, as all benzodiazepines have the same basic 
chemical structure, they all share four principal therapeutic actions to some extent: anxiolytic, 
myorelaxant (muscle relaxant), anticonvulsive, and sedative-hypnotic (Fogelman & Greenblatt, 
2000). 
 Benzodiazepines produce their antianxiety effect by potentiating the neurotransmitter 
gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous 
system that acts in the cortex, substantia nigra, and in the cerebellum.  GABA receptor complexes 
can be divided into two physiologically and pharmacologically distinct subtypes that regulate GABA 
neurotransmission, GABAA and GABAB.  The GABAB receptor subtype is not modulated by 
benzodiazepines and its physiological role is not well known.  However, it appears that GABAB may 
not be linked to anxiety disorders or the effects of anxiolytic medications (Janicak et al., 1993).  
GABAA receptors are, on the other hand, indicated in anxiety disorders and the therapeutic effects 
of benzodiazepines. 
Three subtypes of benzodiazepine receptors exist.  Type 1 receptors, also known as omega-1 
receptors, are located preferentially in the cerebellum and amygdala and seem to be responsible for 
the anxiolytic and sedative responses to benzodiazepines.  Type 2 benzodiazepine receptors, also 
 28
 known as omega-2, are located primarily in the spinal cord and striatum.  As such, these receptors 
may be responsible for mediating the muscle relaxant effects of benzodiazepines.  The last type of 
benzodiazepine receptor, type 3 or omega-3, is located primarily in the peripheral nervous system 
and its role concerning the mediation of the anxiolytic effect of benzodiazepines is unclear (Stahl, 
1996). 
In effect, benzodiazepines facilitate GABA-mediated transmission and thus act as an indirect 
GABAA agonist by enhancing the receptor site affinity of GABA and potentiating its inhibitory 
action.  When benzodiazepines bind to the receptor site, a conformational change takes place and 
the subunit’s affinity for GABA increases.  This increases the probability of GABA binding to its 
receptor site and a net increase in the frequency chloride channel opening, movement of chloride 
into the neuron, and hyperpolarization of the cell.  If GABA is not present in the synapse, 
benzodiazepines have no pharmacological action.  Only when GABA and the benzodiazepine are 
present does the interaction between the medication and the GABA receptor complex promote the 
anxiolytic therapeutic effects of benzodiazepines. 
 A new class of anxiolytics not chemically related to benzodiazepines recently developed is 
azapirone.  Buspirone is the first medication from this class that has been approved for the 
treatment of anxiety.  The therapeutic profile of buspirone, or buspar, is quite different from the 
benzodiazepines in that it has no effect on the GABA receptors.  Instead, buspar seems to act 
primarily at serotonin and dopamine receptor sites.  As such, it does not have the sedative, 
myorelaxant, or anticonvulsive properties seen in benzodiazepines.  While the exact anxiolytic 
mechanism of buspar remains unknown, it appears that buspar act as a partial serotonin agonist at 
postsynaptic receptors and a full agonist at presynaptic receptors (Werry & Aman, 1999).  Thus, 
buspar seems to regulate serotonin systems and return their functioning to normal levels (Fogelman 
& Greenblatt, 2000).  For example, in conditions of serotonin deficiency, buspar’s overall effect is to 
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 increase serotonergic activity.  Currently there are several other azapirones that are being tested for 
their anxiolytic properties; these include drugs such as gepirone, tandospirone, and ipsapirone.  
While promising, some question has arisen as to their efficacy in treating certain anxiety related 
disorders and their overall effectiveness when compared to benzodiazepines. 
Side Effects 
 While the side effects of benzodiazepines are broad, they are generally well tolerated and 
dose dependant.  The most common side effects are drowsiness, sedation, anterograde amnesia, 
impaired psychomotor performance, and ataxia.  The degree of these side effects is, again, related to 
dose and also the particular subgroup of benzodiazepine being used (Maxmen & Ward, 2002).  A 
major concern with this class of medication is its addictive properties.  Those benzodiazepines with 
rapid onset, such as Valium, are much more likely to cause dependence than those with slow onset, 
such as Librium.  However, all benzodiazepines have addictive properties and may also cause 
sweating, nausea, disinhibition, hyperactivity, irritability, and aggressiveness along with a rebound of 
the initial symptoms after discontinuation.  Another concern with the use of benzodiazepines is 
memory impairment and impairment of other cognitive functions.  These effects are particularly 
applicable to the elderly, and individuals with memory impairment, mental retardation or 
developmental disabilities. 
 A major advantage of buspar is its lack of abuse potential.  Also, buspar is non-sedating, 
does not increase an individual’s sensitivity to alcohol, and is not a myorelaxant.  Some common 
side effects include nervousness, dizziness, headache, and some gastrointestinal upsetting.  It appears 
that buspar’s side effect profile is significantly less than those of the benzodiazepines.  However, 
there are some factors that may limit buspar use with some individuals.  One factor is its delayed 
onset of action.  While some benzodiazepines work almost immediately, buspar may take several 
weeks to exert its full therapeutic effect and it must be used regularly during this time.  Another 
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 factor is its effectiveness across a range of anxiety disorders.  As a wide array of benzodiazepines 
exists, a specific medication can be selected to fit the individual and their symptom presentation; the 
same is not true for buspar.  Individuals who have not previously used a benzodiazepine report that 
buspar is very effective in controlling their anxiety while individuals who previously used a 
benzodiazepine reported that buspar was not as effective as their previous medication (Diamond, 
2002).   Research suggests that buspar may be particularly useful for individuals who may be drug 
users and cannot tolerate the various cognitive side effects of the benzodiazepines. 
Antiepileptic Medications 
 Although carbamazepine (CBZ) was developed in the late 1950’s, its antiepileptic properties 
were not reported until 1963.  In the early 1960’s CBZs antiepileptic and psychotropic effects began 
to appear in the research literature (McElroy & Keck, 1995).  In 1974 the U.S. Food and Drug 
Administration (FDA) approved its use as an antiepileptic for adults; in 1978 the FDA approved 
CBZ for use with children, and in 1987 CBZ was approved without an age limitation.  Currently, 
CBZ is a major antiepileptic medication whose use is increasing due to its relatively few 
psychological and neurological toxic side effects.  Since the introduction of CBZ, several other 
antiepileptic medications have been developed or discovered.  However, many of these, such as 
phenobarbital and phenytoin are no longer widely used as they have many behavioral and cognitive 
side effects, some of which are often irreversible (Iivanainen, 1998; Ingram, 1986). 
An alternative antiepileptic being widely used today is valproate, or valproic acid (VPA).  
First discovered in 1882 and used as an organic solvent, the discovery of its antiepileptic properties 
was serendipitous.  VPAs antiepileptic properties were discovered in 1963 in France where VPA was 
originally used to deliver other drugs being tested for their antiepileptic properties.  Researchers 
noted that some compounds, when administered alone, did not have antiepileptic properties.  
However, when these compounds were dissolved in VPA they inhibited seizure activity.  It was soon 
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 concluded that VPA was responsible for this observed result.  Initial clinical trials concerning VPAs 
efficacy as an antiepileptic were conducted in the mid 1960’s and the drug became available in the 
United States in 1978.  As discussed previously, VPA is also currently approved as a mood 
stabilizing medication. 
In addition to CBZ and VPA, benzodiazepines are also used as antiepileptic medications, 
especially clonazepam and clorazepate.  However, while benzodiazepines are considered to be one 
of the safest having fewer severe side effects, it does have significant sedative properties (Mycek, 
Harvey, & Champe, 1997).  Further, its efficacy as an antiepileptic is not well documented and its 
role is typically as a therapeutic adjunct.  There are a number of newer antiepileptic medications such 
as gabapentin, lamotrigine, and vigabatrin that have fewer and less severe side effect profiles 
(Bhaumik, Branford, Duggirala, & Ismail, 1997).  However, few studies can be found on their 
efficacy and use on individuals with mental retardation.  As such, this section will be limited to CBZ 
and VPA, two of the more current and widely used antiepileptic medications.  Although significant 
in the development of antiepileptics, phenobarbital and phenytoin will not be discussed in this 
section. 
Mechanism 
 Carbamazepine is typically used for the control of both partial and generalized tonic-clonic 
seizures and its chemical structure is similar to that of the TCA imipramine.  Its actions can be 
divided into two mechanisms (MacDonald, 1989).  One mechanism involves CBZs effects on 
synaptic and postsynaptic neurotransmitter transmission.  CBZ has been reported to alter 
neurotransmitter concentrations, metabolism, receptors, and second messenger systems (McElroy & 
Keck, 1995).  It is this mechanism that is believed to be responsible for the mood stabilizing effects 
of CBZ.  The second mechanism of CBZ involves its effects on neuronal ion channels that reduce 
high-frequency repetitive firing of action potentials.  Research suggests that this latter mechanism is 
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 responsible for the antiepileptic properties of CBZ (McElroy & Keck, 1995).  Recently, research has 
suggested that CBZ also acts on potassium channels to increase potassium conductance (Post, 
Weiss, & Chuang, 1992).  This may be another possible mechanism explaining the antiepileptic 
properties of CBZ. 
 VPA is useful in controlling a wider variety of seizure types than CBZ including absence, 
myoclonic, tonic-clonic, and complex partial seizures (Vining, Carpenter, & Aman, 1999). The exact 
mechanism that is responsible for valproate’s antiepileptic properties remains unknown.  One theory 
is that VPA exerts its therapeutic effects by changing how the neurotransmitter GABA is 
metabolized (McElroy & Keck, 1995).  VPA seems to inhibit the catabolism of GABA causing an 
increase in GABA release, a decrease in GABA turnover, and increases GABAB receptor density.  
Another theory is that VPA produces its antiepileptic properties by regulating the intake and 
excretion of sodium and potassium (Post, Weiss, & Chuang, 1992).  Further research is needed to 
determine the exact mechanism responsible for VPA’s antiepileptic properties. 
Side Effects 
 CBZ’s side effect profile is somewhat more favorable than those of lithium, antipsychotics, 
and other antiepileptic medications (Smith & Bleck, 1991).  Importantly, CBZ rarely causes EPS or 
renal side effects, and is associated with fewer cognitive and neurological side effects than previous 
antiepileptic medications.  Further, CBZ produces less weight gain, hair loss, and tremor than VPA 
(Diamond, 2002).  However, CBZ does cause increased sedation, has a higher incidence of serious 
side effects, and has the potential to be fatal in an overdose.  Common neurological side effects 
blurred vision, fatigue, nausea, vertigo, and ataxia.  These side effects are dose dependent and most 
disappear after a few weeks.  Some medically dangerous side effects associated with CBZ are 
leukopenia, a drop in the number of available white blood cells; temporary increases in liver 
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 enzymes, and hyponatremia.  Rare side effects are liver problems, hepatic failure, exfoliative 
dermatitis, pancreatitis, and psychological disturbances such as psychosis and mania. 
 Generally, the side effects of VPA are well tolerated and provide a viable alternative for 
many individuals who cannot take other medications a viable alternative (Diamond, 2002).  Research 
indicates that there is a low incidence of adverse effects when compared to lithium, antipsychotics, 
and other antiepileptics including CBZ (Smith & Bleck, 1991).  Further, VPA is less likely to cause 
cognitive impairments as compared to other antiepileptic medications (Vining, 1987).  Like CBZ, 
VPA also has a low incidence of EPS and renal side effects.  However, VPA rarely causes thyroid, 
cardiac, dermatologic, or allergy effects unlike CBZ.  Most side effects of VPA are dose related and 
include gastrointestinal disturbance, sedation, tremor, and weight fluctuations.  Weight gain is the 
most common side effect and seen in approximately half of individuals taking VPA (Diamond, 
2002).  Other common side effects that tend to disappear after a few weeks are nausea, vomiting, 
and indigestion.  Although sedation is a side effect of VPA, it is less common than with CBZ 
(McElroy & Keck, 1995).  More serious side effects are liver toxicity in children and pancreatitis. 
 It is evident that each class of medication and each medication within each class have varying 
therapeutic effects and side effects associated with them that need to be considered when deciding if 
and which medication may be right for an individual.   As mentioned previously, there are several 
guidelines and medication algorithms available to aide clinicians in their choice of medication.  
However, often other factors also play a part in the decision to use psychotropic medications.  For 
example, individuals in large institutions have been shown to receive more antipsychotic medications 
than the general population, especially individuals with mental retardation.  The variance in 
prescribing practices across populations is due to a number of reasons ranging from physicians 
personal preference to the presence of a drug company representative to the type of symptomology 
being treated.  Given the number of medications available and the uses for each, it is important to 
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 look at the reasons behind the use of respective psychotropic medications and the appropriateness 
of their usage in each population. 
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 USE OF PSYCHOTROPIC MEDICATION 
 Given the prevalence and specificity of psychotropic medications, the question of 
appropriate usage arises.  The most common reason for psychotropic medication use is for the 
management of behavioral problems (Clarke, Kelly, Thinn, & Corbett, 1990; Coughlan, 2000; 
Molyneaux, Emerson, & Caine, 1999; Stolker, Heerdink, Leufkens, Clerkx, & Nolen, 2001).  
However, authors such as Aman and Singh (1988), Baumeister, Sevin, and King (1998) and Gadow 
and Poling (1988) have described such practices as controversial for the following reasons: (1) there 
is limited evidence suggesting that such drugs are actually effective in reducing behavior problems, 
and (2) the adverse effects of antipsychotic medications that produce changes in central and 
autonomic nervous system functioning, including tardive dyskinesia, akathisia, and other disorders.  
Further, several studies have reported that the withdrawal or reduction of antipsychotic medication 
had either beneficial or, at least, neutral effects on behavior and increased skill acquisition (Davis et 
al., 1998; La Mendola, Zaharia, & Carver, 1980; Luchins, Dojka, & Hanrahan, 1993). 
When using psychotropic medications to treat behavioral symptoms, clinicians should follow 
specific treatment guidelines or test a specific behavioral-pharmacological hypothesis.  The former 
involves the use of specific guidelines or an algorithm to determine the best course of medication 
for an individual given certain measurable factors such as age, race, diagnosis, and response to 
treatment.  In the latter case, the clinician may suspect that an individual’s behavioral presentation is 
a manifestation of an underlying physiological disorder.  For example, a dysfunction of the 
endogenous opioid system has been implicated in the etiology of self-injury.  Thus, an imbalance in a 
neurotransmitter system is manifested behaviorally as self-injury.  The hypothesis is that an 
individual will engage in self-injury to elevate his level of endogenous opioids, thereby receiving a 
pleasurable response.  This suggests that the primary treatment would be psychopharmacological 
rather than behavioral.  However, a behavioral training program consisting of vigorous, regular 
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 exercise may be used as an adjunctive therapy because it too assists in the elevation of endogenous 
opioids—the so-called “runner’s high” or “being in the zone” effect.  Nonetheless, most individuals 
with mental retardation will not engage in exercise at a consistent level that will produce an increase 
in their endogenous opioids, so a pharmacological intervention would be the treatment of choice, 
with adjunctive behavior therapy. 
In addition to the presence of behavioral and physiological problems, several other 
predictive variables that contribute to the use of such drugs among individuals with mental 
retardation have been identified.  Demographic variables that have not been associated with an 
increase in psychotropic medication use in this population are race/ethnicity (Cullinan, Gadow, & 
Epstein, 1987) and gender (Singh et al., 1997).  However, variables such as age, severity of mental 
retardation, and the restrictiveness and size of facility have all been associated with the use of 
psychotropic medications (Singh et al., 1997).  In some studies, age has been positively correlated in 
older populations, specifically middle-aged adults (Jacobson, 1988), while in others age has been 
found to have no effect (Stolker et al., 2001).  In addition, the severity of an individual’s mental 
retardation has been shown to have an effect on the use of psychotropic medications.  Generally, 
the more severe the individuals’ disability, the greater number and higher the dosage of medications 
prescribed (Aman, Sarphare, & Burrow, 1995; Jacobson, 1988).  Finally, the size and restrictiveness 
of the facility is highly correlated with medication use with the highest effect being in larger and 
more restrictive facilities; these findings hold across both community and institutional settings 
(Aman, Field, & Bridgman, 1985; Singh et al., 1997; Singh & Winton, 1989). 
Not surprisingly, psychiatric diagnosis is highly correlated with the use of psychotropic 
medications in both individuals with and without mental retardation.  While the efficacy of 
medication to treat specific psychiatric disorders has been well established in the literature with 
individuals without mental retardation, there is a paucity of such literature regarding individuals with 
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 mental retardation and developmental disabilities.  Of the literature available, most studies tend to 
focus on the use of antipsychotic medications to treat behavioral problems rather than on 
psychiatric symptomology and their use tends to be based on weak scientific evidence (Singh et al., 
1997).  When comparing the use of psychotropic medications among individuals with and without 
mental retardation, there is a higher prevalence of drug use in the former population (Jacobson, 
1988; Intagliata & Rinck, 1985; Stolker et al., 2001).  However, the appropriateness of these 
prescriptions remains questionable given the difficulty in diagnosing psychiatric disorders in most 
individuals with mental retardation. 
Given that several factors have been identified that predict the use of psychotropic 
medications, the question remains as to the appropriateness of drug usage.  Indeed, if these variables 
predict drug use, are there specific guidelines being followed or a behavioral-pharmacological 
hypothesis being tested?  If the answer is “No,” then the use of psychotropic medications to treat 
psychiatric disorders and behavior problems among individuals with mental retardation becomes 
one of trial and error.  If a drug is to be used, there must be a hypothesized mechanism as to why a 
particular drug would produce beneficial effects, or there is evidence that the specific psychiatric 
disorder being targeted is medication responsive. 
Bates et al., (1986) reported the first study that examined the appropriateness of 
psychotropic medication usage among this population.  They evaluated the appropriateness of 
psychotherapeutic medications regimens of 242 individuals with mental retardation residing in 
institutionalized settings in Ohio.  The sample consisted of 108 women and 134 men who ranged in 
age from 16 to 78 and in level of retardation from mild to profound.  Specifically, Bates et al. 
examined the relationship between medication regimens and psychiatric diagnosis according to 
standards for the treatment of specific psychiatric diagnoses for individuals without mental 
retardation.  The standards used in this study were based on the Manual for Psychiatric Peer Review 
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 (APA, 1981), as well as textbooks in psychiatry (Kaplan & Sadock, 1984) and psychopharmacology 
(Klein, Gittelman, Quitkin, & Rafkin, 1980).  According to the standards used, 45.4% to 60.9% of 
the medication regimens evaluated were rated as appropriate while 39.1% to 54.6% were rated as 
inappropriate across settings. 
Young and Hawkins (2002) reported the only other study to examine the reasons individuals 
with mental retardation are prescribed psychotropic medication.  They examined the psychotropic 
medication regimens of 71 individuals with mental retardation receiving services from a community 
based mental health/mental retardation center in Texas.  The individuals in this survey ranged in age 
from 18 to 80 and included 42 males and 29 females, whose level of mental retardation ranged from 
mild to profound.  To determine the appropriateness of each medication regimen as it related to the 
individual’s psychiatric diagnosis, the authors used prescribing guidelines set forth in the Clinical 
Handbook of Psychotropic Drugs (Bezchlibnyk-Butler, & Jeffries, 1996) for individuals without 
mental retardation.  Based on the standards used, 59% of the medication regimens examined were 
considered appropriate for the targeted diagnosis while 20% were considered inappropriate.  These 
results compared fairly well to those of Bates et al. (1986), especially in terms of the appropriateness 
of drug prescriptions.  Although the inappropriate use of medications was lower in this study, it still 
suggested that many individuals with developmental disabilities were receiving psychotropic 
medications not based on rational pharmacotherapy. 
These two studies advanced our understanding of drug therapy for people with mental 
retardation beyond looking at the prevalence and patterns of drug therapy.  They forged a new 
direction in our research by focusing at the appropriateness of the drug prescription.  While the 
prevalence and patterns of drug prescriptions gives us an overall view of the field, it does little to tell 
us whether rational pharmacotherapy is taking place.  We need to know how drug prescription 
decisions are made. 
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 PURPOSE 
The purpose of this study was to examine the approaches taken in prescribing psychotropic 
drugs to individuals with mental retardation in one state facility.  As stated previously, there are three 
ways of conceptualizing psychopharmacotherapy in people with mental retardation that can be 
documented.  Currently, there is no literature on this subject and it remains unclear how physicians 
are conceptualizing the use of psychopharmacological regimens in individuals with mental 
retardation.  The hypothesis of this study is that the three approaches (primary illness, target 
symptom, and behavioral-pharmacologic) are used equally.  In addition to the primary hypothesis, 
additional analyses will be conducted to examine the presence of any patterns or predictors of 
psychopharmacology in this sample of individuals with mental retardation. 
It behooves us to assess how psychotropic medications are prescribed in people with mental 
retardation and developmental disabilities.  Researchers have shown that the prevalence of 
psychotropic medication use among individuals with mental retardation is relatively high when 
compared to people with other disabilities and that the reasons for these drug prescriptions may not 
be based on rational pharmacotherapy (Bates et al., 1985; Young & Hawkins, 2002).  We need data 
on the prescribing physician/psychiatrist’s adherence to consensus guidelines or algorithms 
developed to enhance rational psychopharmacotherapy.  However, in order to do this we must first 
examine the rationales being used by physicians when they decide to prescribe a medication.  From 
this line of research, instruments and algorithms could be developed that are based on scientific 
evidence and current best practice to aid clinicians in their treatment selection and provide a bridge 





 The sample consisted of individuals residing at Pinecrest Developmental Center (PDC) in 
central Louisiana.  PDC is the largest state-supported residential developmental and training facility 
in Louisiana.  The center provides services to approximately 584 individuals with varying degrees of 
mental retardation and types of developmental disabilities.  Individuals range in age from 8 to 92 
years, and each individual is provided active treatment through a ‘Learning-Based Supports’ Plan 
developed by the individual’s interdisciplinary team.  The subset of individuals that are the focus of 
this study are residents on psychotropic medication for behavior problems or psychiatric disorders 
(n = 87). 
Procedure 
Data on the 87 study participants were collected through the PDC client database and a 
chart review of the individuals on psychotropic medications.  Medications were those prescribed for 
their psychotropic effects with the aim of controlling problem behaviors or specific mental health 
disorders.  Antiepileptic drugs (AEDs) prescribed specifically for seizure disorders were not counted 
as psychotropic drugs.  AEDs prescribed for their psychotropic effects for controlling behavior 
problems (e.g., aggression) or psychiatric symptoms (e.g., mood) were counted as psychotropic 
drugs. 
Data Collection 
In the first step of data collection, the primary researcher collected all sociodemographic 
data from the PDC client database for each of the 87 individuals who were prescribed psychotropic 
medications.  Data were comprised of the following elements: name, age, age group, gender, race, 
primary Axis I diagnosis, disorder type, level of mental retardation, medication, medication type, 
approach type, number of target symptoms and specific target symptoms.  The demographic 
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 variables of interest in this study have shown to be correlated with psychotropic medication use 
(Aman et al., 1995; Aman & Singh, 1988; Bisconer et al., 1996; Singh et al., 1997; Young & Hawkins, 
2002). 
In the second step of data collection, the clinical decision-making of the prescribing 
physician was determined in terms of approaches outlined previously, namely: (a) a target symptom 
approach, (b) a primary illness approach, and (c) a behavioral-pharmacologic hypothesis approach.  
A fourth category (i.e., no apparent approach) was also included for cases where there was no clear 
or documented evidence of a specific approach being taken by the physician.  The approach chosen 
by the prescribing physician for each drug prescription was obtained from each individual’s 
“Learning-Based Supports” Plan - specifically from the Medication Plan section.   
The following algorithm was used as a guide by both the primary and secondary researchers 
to determine which of the three approaches was used by the prescribing physician: 
a. Is the target symptom approach used?  Yes, if: 
I. Specific behaviors, such as aggression or self-injury, are listed as the target of 
medication treatment 
b. Is a primary illness approach used?  Yes, if: 
I. A psychiatric disorder, or specific signs and symptoms of a psychiatric 
disorder, is the listed focus of medication intervention  
c. Is a behavioral-pharmacological hypothesis approach used?  Yes, if: 
I. A specific biological dysregulation is listed as the cause of the behavior being 
treated with medication 
d. If none of the above approaches is used, then: 
I. The prescription was counted as “no apparent approach” for analysis 
purposes. 
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 Data Analysis/Research Design 
 In the first part of this analysis, demographic data were summarized to determine the 
characteristics of the sample population.  In the second part of this analysis, the approaches taken by 
the prescribing physicians were examined.  A Chi Square procedure was used to test the primary 
hypothesis and determine if there were any significant differences between the observed and 
expected frequencies of each approach type.  The expected value for each approach type was set at 
29 (33.3%) because it was predicted each of the approaches (i.e., target symptom, primary illness, 
and behavioral-psychopharmacological hypothesis) would be used equally.  In addition, cross-
tabulations were conducted to examine any patterns in the data regarding approach type by gender, 
race, diagnosis, level of mental retardation, medication type, and age group. 
Inter-rater Reliability 
 A second rater was trained by the primary researcher on how to collect the data.  The 
primary investigator devised ten sample datasets representative of data that would be found in an 
individual’s chart and in the PDC database.  One of these sample datasets was used for training 
where both researchers collected data at the same time.  The remaining datasets were used as 
independent reliability checks.  When 100% agreement was achieved on three of the sample data 
sets the additional rater was considered trained. 
 The primary researcher collected all the socio-demographic data on each of the 87 
individuals receiving psychotropic medications.  The primary researcher and the secondary rater 
collected the same data on 20% (n = 17) of randomly selected individuals from the total sample (N 
= 87) to determine interrater reliability.  Inter-rater reliability was calculated using Cohen’s Kappa 
because this method was specifically developed to measure inter-rater reliability of categorical data 
(Cohen, 1960, 1968; Hartmann, 1977).  The reliability coefficient (Kappa) between the primary 
researcher and the second rater was .92. 
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 RESULTS 
 There were 87 participants with mental retardation who were prescribed at least one 
psychotropic medication for the treatment of an Axis I psychiatric diagnosis or a target behavior 
problem.  Table 1 presents the demographic characteristics of the sample population. 
To examine differences between the observed frequency of the approach types and the 
expected frequencies of the approach types a chi square analysis was conducted.  As shown in Table 
2, the chi square indicated a significant difference between the observed and expected frequencies of 
the approach types x2(2, N = 87) = 115.76, p = .05.  Thus, the hypothesis that each approach type 
would be used equally does not hold.  In prescribing medication for the psychiatric disorders, 
physicians used the primary illness approach with 75 (86%) of the 87 individuals.  They used the 
target symptom approach with 9 (10%) individuals and no apparent rationale with another 3 (4%).  
They did not use the behavioral-pharmacological approach at all. 
 
Table 1.  Demographic characteristics 
Characteristic Frequency Percentage 
Age   
18-41 14 16.1 
42-65 58 66.7 
66-87 15 17.2 
Gender   
Female 38 43.7 
Male 49 56.3 
(table continued)
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 Race   
African-American 16 18.4 
Caucasian 71 81.6 
Level of MR   
Mild 4 4.6 
Moderate 11 12.6 
Severe 13 14.9 
Profound 54 62.1 
Unspecified 5 5.8 
Diagnosis Type   
Anxiety Disorder 13 14.9 
Childhood Disorder 10 11.5 
Mood Disorder 52 59.8 
Psychotic Disorder 12 13.8 
Medication Classes   
Anti-Anxiety 6 6.9 
Antidepressant 27 31.0 
Antipsychotic 37 42.5 
Mood Stabilizer 17 19.5 
 
Table 3 presents the Axis I diagnosis, signs and symptoms targeted by the medication, and 
the class of medication prescribed for the disorder or target behavior.  In 30 cases (35%), no signs 
and symptoms of the disorder were specified and it was unclear as to what behavioral end-points of 
the psychiatric disorder were being targeted by the psychopharmacology treatment plan.  On the 
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 other hand, multiple symptoms (i.e., up to 8) were listed for a single psychiatric disorder and it was 
unclear which symptoms were being targeted.  While an assumption can be made that all listed 
symptoms of the disorder were evident in the individual, there was often no supporting data in the 
individual’s chart to verify this assumption. 
 
Table 2.  Chi Square for observed and expected frequencies of approach type. 
 Frequency 
Approach Type Observed Expected 
Primary Illness 75 29 
Target Symptom 9 29 
Behavioral-Pharmacological 0 29 
 
Table 3.  Primary Axis I diagnosis and symptoms targeted in psychopharmacology treatment plan. 
Subject 
Number





1 Stereotypic Movement Disorder no diagnosis-specific symptoms listed antidepressant 0 
2 Bipolar I Disorder  decreased social contact, distractibility, 
psychomotor agitation, restlessness, 
constant movement 
antipsychotic 5 
3 Bipolar Disorder, NOS irritability, social isolation, psychomotor 
agitation, weight loss, impulsivity 
mood stabilizer 5 
4 Generalized Anxiety Disorder  pacing, difficulty sitting still, fidgeting, 
yelling, screaming, worrying, irritability 
antianxiety 7 
(table continued)
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 5 Bipolar I Disorder crying, psychomotor agitation, increase in 
goal-directed activity 
antipsychotic 3 
6 Mood Disorder, NOS no diagnosis-specific symptoms listed antidepressant 0 
7 Depressive Disorder, NOS crying, irritability, social withdrawal antidepressant 3 
8 Anxiety Disorder, NOS  no diagnosis-specific symptoms listed mood stabilizer 0 
9 Bipolar I Disorder agitation, driven motor activity, irritability, 
poor sleep 
antipsychotic 4 
10 Schizoaffective Disorder delusions, hallucinations, emotional 
lability, crying, depression 
antipsychotic 5 
11 Anxiety Disorder, NOS fidgeting antidepressant 1 
12 Major Depressive Disorder crying, irritability, psychomotor agitation antidepressant 3 
13 Dysthymic Disorder sad affect, crying, increased sleep, fatigue, 
irritability, decreased interest 
antidepressant 6 
14 Bipolar I Disorder no diagnosis-specific symptoms listed mood stabilizer 0 
15 Psychotic Disorder, NOS no diagnosis-specific symptoms listed antipsychotic 0 
16 Bipolar I Disorder increased activity, decreased judgment, 
poor sleep 
antipsychotic 3 
17 Schizophrenia no diagnosis-specific symptoms listed antipsychotic 0 
18 Schizophrenia no diagnosis-specific symptoms listed antipsychotic 0 
19 Bipolar I Disorder decreased sleep, increased activity, 
excessive vocalizations 
mood stabilizer 3 
20 Psychotic Disorder, NOS no diagnosis-specific symptoms listed antipsychotic 0 
21 Bipolar Disorder, NOS psychomotor agitation, decreased sleep, 
impulsivity, increased activity, crying, 
excessive vocalizations 
mood stabilizer 6 





 23 Bipolar I Disorder increased activity, decreased sleep, 
elevated mood, irritability 
mood stabilizer 4 
24 Disruptive Behavior Disorder, 
NOS 
irritability, aggression, impulsivity antipsychotic 3 
25 Mood Disorder, Depressed irritability, sleep disturbance, 
psychomotor agitation, depressed mood 
antidepressant 4 
26 Bipolar Disorder, NOS no diagnosis-specific symptoms listed antipsychotic 0 
27 Bipolar I Disorder irritability, psychomotor agitation, sleep 
disturbance 
antipsychotic 3 
28 Bipolar I Disorder no diagnosis-specific symptoms listed antipsychotic 0 
29 Bipolar I Disorder irritability, psychomotor agitation, 
pressured speech, poor concentration 
mood stabilizer 4 
30 Bipolar I Disorder lethargy, decreased appetite, decreased 
interactions, irritability, sleep disturbance, 
increased speech 
antipsychotic 6 
31 Bipolar I Disorder psychomotor agitation, irritability, 
decreased sleep 
mood stabilizer 3 
32 Dysthymic Disorder depressed mood, decreased energy, 
crying, psychomotor agitation 
antidepressant 4 
33 Bipolar I Disorder psychomotor acceleration, sleep 
disturbance, impulsivity 
mood stabilizer 3 
34 Disruptive Behavior Disorder, 
NOS 
no diagnosis-specific symptoms listed antipsychotic 0 
35 Psychotic Disorder, NOS no diagnosis-specific symptoms listed antipsychotic 0 
36 Bipolar I Disorder no diagnosis-specific symptoms listed mood stabilizer 0 
37 Psychotic Disorder, NOS  no diagnosis-specific symptoms listed antipsychotic 0 
(table continued)
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 38 Bipolar I Disorder psychomotor agitation, decreased sleep, 
crying 
antidepressant 3 
39 Bipolar I Disorder increased activity, psychomotor 
agitation, flat affect, sleep disturbance 
mood stabilizer 4 
40 Bipolar Disorder, NOS psychomotor agitation antipsychotic 1 
41 Bipolar I Disorder psychomotor agitation, impulsivity, 
reduced sleep, increased vocalizations 
antipsychotic 4 
42 Schizophrenia no diagnosis-specific symptoms listed antipsychotic 0 
43 Schizoaffective Disorder no diagnosis-specific symptoms listed antipsychotic 0 
44 Bipolar I Disorder psychomotor agitation, sleep disturbance, 
crying 
antipsychotic 4 
45 Generalized Anxiety Disorder worrying antidepressant 1 
46 Stereotypic Movement Disorder skin picking, hand shaking antipsychotic 2 
47 Generalized Anxiety Disorder worrying, restlessness, decreased sleep, 
irritability 
antianxiety 4 
48 Mood Disorder, NOS no diagnosis-specific symptoms listed antidepressant 0 
49 Schizophrenia attending to internal stimuli, bizarre 
motor posturing, paranoia, flat affect 
antipsychotic 4 
50 Depressive Disorder, NOS crying, irritability, poor sleep antidepressant 3 
51 Anxiety Disorder, NOS worrying, nervousness antianxiety 2 
52 Major Depressive Disorder no diagnosis-specific symptoms listed antidepressant 0 
53 Bipolar I Disorder agitation, decreased sleep, increased 
motor activity 
mood stabilizer 3 
54 Bipolar Disorder, NOS no diagnosis-specific symptoms listed antipsychotic 0 
55 Bipolar Disorder, NOS hypersomnia, weight loss, irritability, 
decreased engagement, social withdrawal 
antidepressant 5 
(table continued)
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 56 Bipolar Disorder, NOS irritability, psychomotor agitation, sleep 
disturbance 
mood stabilizer 3 
57 Post Traumatic Stress Disorder no diagnosis-specific symptoms listed antidepressant 0 
58 Psychotic Disorder, NOS no diagnosis-specific symptoms listed antipsychotic 0 
59 Pica no diagnosis-specific symptoms listed antidepressant 0 
60 Intermittent Explosive Disorder no diagnosis-specific symptoms listed antidepressant 0 
61 Bipolar I Disorder decreased sleep, psychomotor agitation, 
crying, weight loss 
antipsychotic 3 
62 Bipolar Disorder, NOS psychomotor agitation, elevated mood, 
decreased sleep, irritability 
antipsychotic 4 
63 Stereotypic Movement Disorder no diagnosis-specific symptoms listed antipsychotic 0 
64 Obsessive-Compulsive Disorder hoarding, repetitive cleaning antidepressant 2 
65 Post Traumatic Stress Disorder repeatedly discussing past abuse, 
nightmares, avoidance, exaggerated 
startle response, trembling 
antidepressant 6 
66 Anxiety Disorder, NOS sleep disturbance, irritability, restlessness, 
muscle tension 
antianxiety 4 
67 Bipolar I Disorder no diagnosis-specific symptoms listed antipsychotic 0 
68 Depressive Disorder, NOS depressed mood, crying, irritability, 
insomnia, fatigue, psychomotor retardation 
antidepressant 6 
69 Bipolar I Disorder decreased sleep, psychomotor agitation, 
social withdrawal 
antipsychotic 3 
70 Psychotic Disorder, NOS hallucinations, paranoia antipsychotic 2 
71 Bipolar Disorder, NOS easily distracted, extremely talkative, 
irritability, psychomotor agitation 
antipsychotic 4 
72 Anxiety Disorder, NOS no diagnosis-specific symptoms listed antianxiety 0 
(table continued)
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 73 Bipolar I Disorder decreased sleep, crying, psychomotor 
agitation 
mood stabilizer 3 
74 Anxiety Disorder, NOS restlessness antidepressant 1 
75 Bipolar II Disorder sleep disturbance, distractibility, 
psychomotor agitation 
antipsychotic 3 
76 Major Depressive Disorder social isolation antidepressant 1 
77 Bipolar Disorder, NOS decreased sleep, irritability, increased 
activity, pressured speech 
mood stabilizer 4 
78 Major Depressive Disorder irritability, anhedonia, sleep disturbance, 
lethargy, depressed mood, decreased 
appetite, distractibility, social withdrawal 
antidepressant 8 
79 Major Depressive Disorder psychomotor agitation, depressed mood, 
crying, sleep disturbance, lack of interest 
antidepressant 5 
80 Mood Disorder, NOS no diagnosis-specific symptoms listed antipsychotic 0 
81 Major Depressive Disorder irritability, restlessness, social isolation,  
weight loss, psychomotor retardation 
antidepressant 5 
82 Depressive Disorder, NOS social isolation, irritability, decreased  
appetite, decreased interest, lethargy 
antidepressant 5 
83 Pica no diagnosis-specific symptoms listed antianxiety 0 
84 Bipolar I Disorder no diagnosis-specific symptoms listed mood stabilizer 0 
85 Stereotypic Movement Disorder no diagnosis-specific symptoms listed antipsychotic 0 
86 Bipolar II Disorder sleep disruption, agitation, decreased 
appetite 
mood stabilizer 3 




 Table 4 presents the Axis I psychiatric diagnosis and the specific medications prescribed for 
each of them by the number of individuals with each of the disorders.  Especially for those more 
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 frequently occurring disorders, there was no clear information in each individual’s medical chart why 
one drug was chosen over another. 
 Cross tabulation analyses were conducted to explore any relationships among the data 
collected.  These analyses showed that of the 75 cases following a primary illness approach, 47 
(62.7%) had a diagnosis of a mood disorder, 11 (14.7%) had a diagnosis of an anxiety disorder, 9 
(12%) had a diagnosis of a psychotic disorder and 8 (10.7%) had a diagnosis of a childhood disorder.  
Of these 75 cases, 47 (62.7%) were individuals with profound mental retardation, 12 (16%) with 
severe mental retardation, 8 (10.7%) with moderate mental retardation, 4 (5.3%) with mild mental 
retardation and 4 (5.3%) with unspecified level of mental retardation.  In 31 (41.3%) cases, the 
individuals were prescribed an antipsychotic medication, 24 (32%) were prescribed an anti-
depressant, 14 (18.7%) a mood stabilizer and 6 (8%) were prescribed an anxiolytic.  Further, 11 of 
the 75 individuals (14.7%) were between the ages of 18 and 41, 49 (65.3%) were between the ages of 
42 and 65, and 15 (20%) were between the ages of 66 and 87.  Of the 75, 60 (80%) individuals were 
Caucasian and 15 (20%) were African Americans; 35 (46.7%) were females. 
 
Table 4.  Diagnosis and medications prescribed by approach taken. 
Primary Illness Approach 
Primary Diagnosis Medication Prescribed Total 
























Bipolar II Disorder Depakote (1) 
Olanzapine (1) 
2 









 Dysthymic Disorder Paxil (2) 2 
Generalized Anxiety Disorder Clonazepam (2) 
Paxil (1) 
3 
Intermittent Explosive Disorder Depakote (1) 1 




 Serzone (1)  
Mood Disorder, Depressed Paxil (1) 1 
Mood Disorder, NOS Prozac (2) 2 
Obsessive-Compulsive Disorder Luvox (1) 1 
Pica Clonazepam (1) 
Luvox (1) 
2 
Post Traumatic Stress Disorder Zoloft (1) 1 
Psychotic Disorder Olanzapine (4) 
Seroquel (1) 
5 
Schizoaffective Disorder Olanzapine (1) 1 
Schizophrenia Olanzapine (2) 
Seroquel (1) 
3 
Stereotypic Movement Disorder Risperidone (2) 2 




 Target Symptom Approach 
Target Symptom Medication Prescribed Total 
Aggression Neurontin 1 
Aggression Lithium 1 
Aggression Olanzapine 1 
Aggression Abilify 1 
Aggression Risperidone 1 
Hallucinations Risperidone 1 
Weight Loss Mellaril 1 
Sleep Disturbance Zoloft 1 
Involuntary Movement Olanzapine 1 
Total 9 
No Apparent Approach 
Primary Diagnosis Medication Prescribed Total 
Stereotypic Movement Disorder Luvox 1 
Major Depressive Disorder, NOS Zoloft 1 
Bipolar I Disorder Depakote 1 
Total 3 
  
 Of the nine individuals whose psychopharmacology plan followed a target symptom 
approach, 3 (33.3%) had a diagnosis of a mood disorder, 3 (33.3%) had a diagnosis of a psychotic 
disorder, 2 (22.2%) had a diagnosis of an anxiety disorder, and 1 (11.1%) had a diagnosis of a 
childhood disorder.  Six (66.7%) individuals were diagnosed with profound mental retardation, 2 
(22.2%) with moderate mental retardation, and 1 (11.1%) with severe mental retardation.  An 
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 antipsychotic was prescribed to 6 (66.7%) of these 9 individuals.  In 2 (22.2%) cases, the individual 
was prescribed a mood stabilizer and in 1 (11.1%) case an antidepressant.  Anxiolytic medications 
were not prescribed in this group.  Further, 3 (33.3%) individuals were between the ages of 18 and 
41 and 6 (66.7%) were between the ages of 42 and 65. and.  Eight (88.9%) of the 9 individuals were 
Caucasian and 1 (11.1%) was an African American; 8 (88.9%) were males. 
 Of those three individuals whose psychopharmacology plan followed an apparent approach, 
2 (66.7%) had a diagnosis of a mood disorder and the other had a diagnosis of a childhood disorder.  
One of these individuals was diagnosed with profound mental retardation, another was diagnosed 
with moderate mental retardation and the third had an unspecified level of mental retardation.  Two 
individuals (66.7%) of were prescribed an antidepressant and the other individual was prescribed a 
mood stabilizer.  All three of these individuals were from the 42 to 65 age group, all three were 




 The results showed that physicians at one facility for individuals with developmental 
disabilities typically used a primary illness approach in prescribing psychotropic medication for Axis 
I psychiatric disorders.   Of the 87 individuals prescribed psychotropic medications for Axis I 
psychiatric disorders, 75 of them had a psychopharmacology treatment plan derived from a primary 
illness approach.  This approach assumes that the behavioral end-points of the psychiatric disorder 
can be managed, controlled or eliminated by treating the disorder itself.  For example, aggression 
arising from command hallucinations can be reduced or eliminated by treating hallucinations 
without specifically targeting the aggression itself.  
 The primary illness approach provides clinicians with a method of conceptualizing an 
individual’s treatment plan before they begin actual treatment.  It enables an interdisciplinary 
treatment team to determine how different symptoms and behaviors will be treated, and how to 
integrate psychopharmacological, behavioral and other treatments.  For example, when presented 
with an individual who has an Axis I diagnosis of schizophrenia and an Axis II diagnosis of mild 
mental retardation, the treatment team typically determines the nature and manifestations of the 
schizophrenia in the individual prior to developing a treatment plan.  The individual may present as 
having command hallucinations that tell him to hurt himself and others, and is uncommunicative, 
withdrawn, does not engage in activities of daily living skills (ADL skills), and is not motivated to 
initiate or engage in assigned tasks.   
 In this case, the treatment team must decide if taking a primary illness approach will control 
and manage his positive symptoms of schizophrenia (i.e., command hallucinations, aggression), as 
well as his negative symptoms (i.e., uncommunicative, withdrawn, does not engage in activities of 
daily living skills, and is not motivated to initiate or engage in assigned tasks).  The physician may 
determine that a drug prescription would be appropriate for the positive symptoms but that it may 
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 not greatly affect this individual’s negative symptoms.  Thus, the team may use a primary illness 
approach to treat the command hallucinations, thereby taking care of the aggression resulting from 
command hallucinations.  Thus, no behavioral intervention may be necessary specifically for 
aggression.  Further, the team may decide that while some benefits may accrue in the negative 
symptoms due to the drug treatment for hallucinations, the negative symptoms are compounded 
with the individual’s Axis II diagnosis of mental retardation and that there is an associated skills 
deficit in communication, social skills and ADL skills.  Thus, a target symptom approach would be 
taken and the treatment plan includes skills training programs. 
 The primary illness approach works best in an integrated treatment planning system where 
all disciplines provide input into the treatment plan.  It also enhances the treatment team’s ability to 
integrate different treatment modalities within a single treatment plan (Singh et al., 2002), particularly 
behavioral and psychopharmacological.  However, it does require the treatment team to have a good 
understanding of the psychopharmacology of developmental disabilities in terms of Axis I 
psychiatric disorders.  For example, they need to know which drugs are effective with positive 
symptoms, negative symptoms, or both.  Current research suggests that the typical antipsychotic 
medications target the positive symptoms of schizophrenia while the atypical antipsychotic 
medications target both positive and negative symptoms, and, within the atypical group, Olanzapine 
appears to be most effective with negative symptoms (Emsley & Oosthuizen, 2003). The typical 
antipsychotics tend have more cognitive side effects such as memory and concentration problems, 
trouble with executive functioning, and attention.  Thus, physicians will need to have a good 
working knowledge of the various effects and side effects of psychotropic medications so that they 
can assist the treatment team to develop the best combination of treatments for specific disorders in 
a given individual. 
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  The target symptom approach was used far less often, only 10% in this sample of 87 
individuals.  This approach assumes that there is a specific problem that needs treatment, and that 
there is a specific treatment for the problem.  This approach does not assume that the specific 
treatment will also ameliorate the underlying psychopathology that is the cause of the problem 
although it may.  For example, in general medicine, an individual may present with fever that is high 
enough to warrant immediate treatment regardless of the underlying medical condition that gave rise 
to it.  The fever is treated as a target symptom and brought under control while tests are undertaken 
to find the cause of the fever.  Sometimes, the cause of the fever may be apparent (e.g., recurrence 
of cancer) but it cannot be treated and palliative medical treatment is provided for the cancer. 
 Similarly, in developmental disabilities, an individual may exhibit aggressive behavior that is 
of high frequency and intensity and present a danger to self or others.  The origin of the aggressive 
behavior may be faulty learning and therefore treated via behavioral methods.  This would be a good 
example of a target symptom approach.  An alternative would be that the aggressive behavior is a 
manifestation of psychosis that is a part of the schizophrenia symptomatology of the individual.  In 
this case, because the aggressive behavior is dangerous to self or others and the psychosis is not well 
controlled with current medication, a target symptom approach may be taken to control the 
aggression while further tests and analyses are completed and a new psychopharmacology plan is 
developed.  A further alternative would be that the aggression is sometimes an outcome of the 
psychosis and is an instrumental response at other times.  In this case, a combined primary illness 
and target symptom approach would be appropriate, as in combined pharmacological-behavioral 
treatments. 
 In this facility, only 10% (n = 9) of the drug prescriptions were based on a target symptom 
approach.  However, it was unclear from the medical records of the nine individuals if the behaviors 
targeted were only instrumental in nature or had any psychiatric symptoms.  There was one specific 
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 case in which a target symptom approach was used with a behavior (i.e., hallucinations) that is 
typically a symptom of psychosis.  In this case, the hallucinations were unrelated to an Axis I 
disorder and the symptom was treated pharmacologically as a target behavior. There were five cases 
in which aggression was treated with psychotropic medication, but in each of these cases there was 
an associated behavioral plan for the reduction of the instrumental component of the aggression.  
What was not clear from the medical records was the underlying psychopathology of the aggression 
that made the behavior responsive to medication.  In one case, involuntary movement was 
apparently treated with Olanzapine.  It was not clear from the medical records why this drug was 
deemed appropriate for this behavior. 
 The behavioral-pharmacological hypothesis approach provides clinicians a useful way of 
conceptualizing treatment when there is clear empirical evidence that a certain drug may be effective 
for a given behavior because there is a hypothesized mechanism of action that may account for the 
effectiveness of the drug.  For example, individuals with developmental disabilities engage in self-
injury for a variety of reasons, including biological, maladaptive learning, and environmental reasons 
(Schroeder, Oster-Granite, & Thompson, 2002). There are two opiate hypotheses regarding self-
injury in some individuals and their treatment.  In the first hypothesis, it is assumed that self-injury 
results from general sensory depression and an insensitivity to pain that may be related to chronic 
elevations of endogenous opiates (Sandman & Hetrick, 1995).  In the second hypothesis, it is 
assumed that self-injury functions to release β-endorphins and enables the individual to achieve an 
opiate “high” (Sandman & Hetrick, 1995).  In either case, the self-injury can be treated successfully 
with opiate blockers, such as naloxone and naltrexone (Sandman et al., 2000).  The behavioral-
pharmacological hypothesis was not used in this facility. 
 There were three cases where it was totally unclear as to the rationale used by the physician 
to prescribe the psychotropic medication.  The data in the individuals’ medical charts did not 
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 contain any psychopharmacology plan or an explanation of the reasons why the drugs were 
prescribed. 
 In general, the documentation in the charts regarding assessments, diagnostic formulation, 
differential diagnosis, and rationale of pharmacotherapy was not very clear or missing.  Often, the 
signs and symptoms of the disorders were listed but it was not made clear if the individual 
manifested some or all of them.  In many cases, the symptoms listed were generic and not 
individualized.  For example, for an individual with schizophrenia, the symptoms were listed as 
auditory hallucinations, delusions, and thought disorder without any specifications as to the form 
and content.  In other cases, the listed symptoms did not comport to the given diagnosis.  For 
example, in one case, the single symptom listed for Major Depressive Disorder was social isolation.  
It could be that all other symptoms were well controlled by medication and psychosocial 
interventions or that the given diagnosis is open to question.  Further, there were 30 (34.5%) 
individuals with a “not otherwise specified” diagnosis.  While this is a legitimate diagnosis, if it is 
arrived at by eliminating all other possibilities that would account for the observed signs and 
symptoms, there was very limited documentation of differential diagnosis leading to a “not 
otherwise specified” diagnosis. 
 One of the limitations of this study is that there was no accounting for appropriate 
assessment and diagnosis.  It was assumed that appropriate assessments informed the diagnosis and 
that the diagnosis informed further assessments for differential diagnosis.  This was not assessed and 
it is possible, at least for some individuals, that their diagnosis was incorrect, as reported in previous 
studies (e.g., Bates et al., 1985), and that they were inappropriately medicated.  Future studies should 
investigate the accuracy of the diagnostic formulation and differential diagnosis. 
 Future studies should also investigate the appropriateness of the medications prescribed for 
the purported diagnosis.  In this study, it was noted that several medications were prescribed for 
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 given disorders and there was no clear rationale for choosing one drug over another.  In one of the 
few studies that investigated this issue in a small sample of individuals, it was found that there were 
mismatches between the disorder and the drug prescribed (Young & Hawkins, 2002).  Further 
studies are needed to corroborate this finding.  In addition, given that the field of 
psychopharmacology in developmental disabilities now has a psychopharmacology consensus 
handbook (Reiss & Aman, 1998) as well as expert consensus guidelines (Rush & Frances, 2002), it is 
an opportune time to use these as the basis for determining the quality of the match between the 
diagnosis and the prescribed medication. 
 In summary, the results of this study showed that physicians at one developmental center 
rely mainly on a primary illness approach to prescribe psychotropic medication to individuals with 
developmental disabilities who have an Axis I psychiatric disorder.  To a much lesser extent, they 
use a target symptom approach.  No variables were apparent that predicted the use of a specific 
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